Loading Programs

Available Programs > Online On-Demand

Programs Search and Views Navigation

February 2021

  • ONLINE ON-DEMAND

Getting Ahead of Migraine: Best Practices for Migraine Prevention – Migraine Diagnosis and Burden of Disease

February 26, 2021 - February 26, 2022

My migraines made me feel like I was a part-time parent. They were so bad that my husband and I came to the difficult decision that we could not have more kids because I could not function as a parent ‒ I could barely function as an adult.” Do you know how migraine affects the daily lives of your patients? Join Dr Cynthia Armand and Dr Carrie Dougherty to learn more about caring for patients with this debilitating disease. Cynthia…

Find out more »
  • ONLINE ON-DEMAND

Getting Ahead of Migraine: Best Practices for Migraine Prevention – Targeting CGRP for Migraine Prevention

February 26, 2021 - February 26, 2022

Four anti-calcitonin gene-related peptide (CGRP) monoclonal antibodies are approved for migraine prevention. To ensure clinicians are prepared to consider these agents when clinically indicated, this educational activity will compare the efficacy and safety of these therapies for migraine prevention and discuss strategies for shared decision-making. Cynthia E. Armand, MD, Assistant Professor of Neurology Albert Einstein College of Medicine, Fellowship Director Montefiore Headache Center, Bronx, NY Carrie Dougherty, MD, FAHS, Associate Professor of Neurology Program Director, Headache Medicine Fellowship, Assistant Program Director, Neurology…

Find out more »
  • ONLINE ON-DEMAND

HER-Directed Therapies in Metastatic Breast Cancer: Safety and Efficacy Considerations

February 22, 2021 - February 22, 2022

Despite advances in HER targeting, HER2-positive metastatic breast cancer typically progresses. Research has established that the HER2-HER3 complex is the true driver of HER2-amplified cancer and the effective inactivation of this complex is the new bar for novel therapies. In this interactive educational activity, Dr Hurvitz and Dr Tolaney share key data and expert perspectives on recently approved and emerging HER-targeted therapies for metastatic breast cancer. Sara A. Hurvitz, MD, FACP, Professor of Medicine, Director, Breast Oncology Program, Division of…

Find out more »
  • ONLINE ON-DEMAND

Clinical Pearls for Advanced Practice Providers: Reversing Direct Oral Anticoagulants in the Emergency Department – ACEP Frontline Podcast

February 15, 2021 - February 15, 2022

This online educational podcast offers clinical pearls for the assessment of bleeding severity in patients receiving DOACs; expert-guided insights to rapid reversal of urgent DOAC-associated bleeding; and practical strategies for aligning clinical practice with local hospital bleeding management protocols. Join Dr Colin Kaide and Eric Cucchi as they examine the latest recommendations for the management of life-threatening DOAC-associated bleeding. Click here to enroll and listen to this 37-minute ACEP Frontline Podcast: https://www.acep.org/education/podcasts-and-apps/  

Find out more »
  • ONLINE ON-DEMAND

New Therapeutic Options in AML: An Update for Community Clinicians – Podcast

February 11, 2021 - February 11, 2022

Have you heard about the latest clinical advances in AML therapy? Recent approvals and emerging therapies, such as epigenetic agents and newer cytotoxics, has transformed the care of patients with newly diagnosed and relapsed/refractory AML. Join Dr Stephen A. Strickland and Dr Eunice S. Wang as they discuss recent science that provides guidance for the care team on the use of newly approved and novel strategies for AML management. Click here to listen to this 45-minute CME podcast: https://www.mycme.com/courses/new-therapeutic-options-in-aml-an-update-for-community-clinicians-7573

Find out more »
  • ONLINE ON-DEMAND

Team Up Against MS: The Multidisciplinary Patient-Centered Team Approach to Multiple Sclerosis – Podcast

February 8, 2021 - February 8, 2022

Patients with multiple sclerosis (MS) often need the intervention of multiple specialists, resulting in a complex organization of care. Listen in to this team of healthcare professionals from the MS Comprehensive Care Center at Holy Name Medical Center, who share their insights on best practices for patient-centered care of people with MS. The MS Care Team share key aspects of their evolution as a team using two cases of patients with MS. This discussion highlights how they 1) evaluate existing…

Find out more »

January 2021

  • ONLINE ON-DEMAND

Advances in the Multidisciplinary Care of Patients with Tenosynovial Giant Cell Tumor – Gather-ed Activity

January 15 - March 31

Tenosynovial giant cell tumor (TGCT), a rare, nonmalignant tumor, arises from synovium in joints, bursae, and tendon sheaths. The diffuse type often presents aggressively, with high recurrence rates following surgery. The FDA recently approved the first medication for adult patients with symptomatic TGCT associated with severe morbidity or functional limitations and not amenable to improvement with surgery. Individualized treatment plans should be created for patients by evaluating the benefits and risks of surgery and medications, as well as the type…

Find out more »

December 2020

  • ONLINE ON-DEMAND

The Time Is Now: Advancing the Care of Adolescent and Adult Patients With Sickle Cell Disease

December 31, 2020 - December 31, 2021

Did you know the average life span of Americans with sickle cell disease is 20 to 30 years less than those without sickle cell disease? New clinical approaches and treatments can lead to increased survival. In this 30-minute CME activity, Dr Biree Andemariam and Dr Laura De Castro explore current evidence-based approaches, review available agents, and discuss strategies to encourage clinical trial participation among patients. Join us to learn the latest information on this challenging disease. https://www.mycme.com/courses/the-time-is-now-advancing-the-care-of-adolescent-and-adult-patients-with-sickle-cell-disease-7500    

Find out more »
  • ONLINE ON-DEMAND

Moving the Needle: Collaborative Strategies to Overcome Barriers to Insulin Initiation and Adherence – Strategies to Improve Uptake and Adherence to Insulin

December 22, 2020 - December 22, 2021

Diabete-s represents a significant national and global health concern, affecting nearly 11% of the population in the United States. Despite established benefits of insulin, it continues to be underused and many patients fail to achieve glycemic goals. Three 15-minute CME modules will review patient and clinician barriers that delay insulin initiation, communication strategies to address barriers to insulin therapy, and how to develop patient-specific plans for insulin therapy according to clinical and safety data. These educational activities will prepare clinicians…

Find out more »
  • ONLINE ON-DEMAND

Moving the Needle: Collaborative Strategies to Overcome Barriers to Insulin Initiation and Adherence – Recommendations for the Role and Use of Insulin

December 22, 2020 - December 22, 2021

Diabetes represents a significant national and global health concern, affecting nearly 11% of the population in the United States. Despite established benefits of insulin, it continues to be underused and many patients fail to achieve glycemic goals. Three 15-minute CME modules will review patient and clinician barriers that delay insulin initiation, communication strategies to address barriers to insulin therapy, and how to develop patient-specific plans for insulin therapy according to clinical and safety data. These educational activities will prepare clinicians…

Find out more »
  • ONLINE ON-DEMAND

Moving the Needle: Collaborative Strategies to Overcome Barriers to Insulin Initiation and Adherence – Patient and Provider Barriers to Insulin Uptake and Adherence

December 22, 2020 - December 22, 2021

Diabetes represents a significant national and global health concern, affecting nearly 11% of the population in the United States. Despite established benefits of insulin, it continues to be underused and many patients fail to achieve glycemic goals. Three 15-minute CME modules will review patient and clinician barriers that delay insulin initiation, communication strategies to address barriers to insulin therapy, and how to develop patient-specific plans for insulin therapy according to clinical and safety data. These educational activities will prepare clinicians…

Find out more »
  • ONLINE ON-DEMAND

Following the Trail of Evidence to Individualize and Optimize Multiple Sclerosis Care: Exploring the Use of Diagnostic Tools to Improve Early Detection of MS

December 21, 2020 - December 21, 2021

Multiple sclerosis (MS) is a progressive disease that causes irreversible damage to the central nervous system (CNS). This disabling neurologic disease is one of the most common causes of disability in individuals between the ages of 10 and 65 years old. It presents with a wide range of symptoms and therefore has a variable impact on motor and cognitive function, activities of daily living, and patient quality of life. Three-fourths of MS patients eventually become significantly disabled by this condition.…

Find out more »
  • ONLINE ON-DEMAND

Following the Trail of Evidence to Individualize and Optimize Multiple Sclerosis Care: Examining the Evidence for Early Initiation of Disease-Modifying Therapy

December 21, 2020 - December 21, 2021

Multiple sclerosis (MS) is a progressive disease that causes irreversible damage to the central nervous system (CNS). This disabling neurologic disease is one of the most common causes of disability in individuals between the ages of 10 and 65 years old. It presents with a wide range of symptoms and therefore has a variable impact on motor and cognitive function, activities of daily living, and patient quality of life. Three-fourths of MS patients eventually become significantly disabled by this condition.…

Find out more »
  • ONLINE ON-DEMAND

Following the Trail of Evidence to Individualize and Optimize Multiple Sclerosis Care: Clinical Insights on When and How to Switch DMT in Patients with a Suboptimal Treatment Response

December 21, 2020 - December 21, 2021

Multiple sclerosis (MS) is a progressive disease that causes irreversible damage to the central nervous system (CNS). This disabling neurologic disease is one of the most common causes of disability in individuals between the ages of 10 and 65 years old. It presents with a wide range of symptoms and therefore has a variable impact on motor and cognitive function, activities of daily living, and patient quality of life. Three-fourths of MS patients eventually become significantly disabled by this condition.…

Find out more »
  • ONLINE ON-DEMAND

Breakthroughs and Innovations: Managing Complex Cases in Graft-versus-Host Disease

December 2, 2020 - December 2, 2021

Acute graft-versus-host disease (aGVHD) is a common complication of allogeneic hematopoietic stem cell transplantation and is a major cause of morbidity and mortality. While systemic corticosteroids are traditional first-line treatment for aGVHD, about half of patients are refractory to therapy. So what options are available for the treatment of steroid-refractory aGVHD? Join Doris Ponce, MD, and Corey Cutler, MD, MPH, for this podcast as they discuss different novel therapeutic options for managing aGVHD refractory to steroids. This activity is jointly…

Find out more »
  • ONLINE ON-DEMAND

Changing Course: Reversing Direct Oral Anticoagulants in the Emergency Department

December 1, 2020 - December 1, 2021

The development of direct oral anticoagulants (DOACs) has advanced the therapeutic landscape for the management of thromboembolic events. Specific agents that rapidly reverse the effects of DOACs are now available and offer safe and effective options for patients who experience an emergency DOAC-associated bleeding event. This interactive activity will offer clinical pearls for the assessment of bleeding severity in patients receiving DOACs; expert-guided insights to rapid reversal of urgent DOAC-associated bleeding; and clinical decision support tools to optimize outcomes in…

Find out more »

November 2020

  • ONLINE ON-DEMAND

Collaborating to Overcome Lifelong Challenges in Hemophilia A: Adherence in Hemophilia A

November 17, 2020 - November 17, 2021

How do you encourage medication adherence in your patients with hemophilia A? Several factors influence treatment adherence in hemophilia A, such as understanding treatment benefits, disease severity, venous access, clinic transitions, and insurance coverage. This educational activity discusses adherence barriers, strategies to promote adherence, and the role of the care team to address adherence in this population. Jordan A. Shavit, M.D., Ph.D. Medical Oncologist, Sarcoma Oncology Center Santa Monica, CA Medical Advisor, Hemophilia Foundation of Southern California Pasadena, CA Medical…

Find out more »
  • ONLINE ON-DEMAND

Collaborating to Overcome Lifelong Challenges in Hemophilia A: Management of Inhibitors in Hemophilia A

November 17, 2020 - November 17, 2021

Inhibitors affect approximately 30% of patients with severe hemophilia A. In addition to substantial treatment and medical costs, patients with hemophilia who have inhibitors are twice as likely to be hospitalized for a bleeding complication. This educational activity addresses risk factors for inhibitor development, testing and monitoring strategies, the role of immune tolerance induction, and the use of bypassing agents in the setting of an inhibitor. Jordan A. Shavit, M.D., Ph.D. Medical Oncologist, Sarcoma Oncology Center Santa Monica, CA Medical…

Find out more »
  • ONLINE ON-DEMAND

Collaborating to Overcome Lifelong Challenges in Hemophilia A: Personalizing Hemophilia A Prophylaxis Regimens

November 17, 2020 - November 17, 2021

Are you confident selecting between available therapies for hemophilia A? Over the past few decades, the care for patients with hemophilia A has drastically improved, while also becoming more complex, with the advent of new therapeutic options for this challenging disease. This educational activity reviews FDA-approved and investigational products used for this disease and the corresponding data for these agents. Jordan A. Shavit, M.D., Ph.D. Medical Oncologist, Sarcoma Oncology Center Santa Monica, CA Medical Advisor, Hemophilia Foundation of Southern California…

Find out more »
  • ONLINE ON-DEMAND

Moving the Needle: Collaborative Strategies to Overcome Barriers to Insulin Initiation and Adherence – Gather-ed Activity

November 4, 2020 - May 31, 2021

Are you confident initiating and managing insulin in your clinical practice? With the number of adults with type 2 diabetes estimated to increase to over 60 million by 2060, more patients will require insulin and more strain will be placed on clinicians in the health care system. This educational activity will be delivered via an innovative online platform and led by faculty experts in diabetes using virtual small groups of learners to drive discussion and learning through assessments, self-study modules,…

Find out more »

September 2020

  • ONLINE ON-DEMAND

Matching the Tool to the Job: Individualizing Treatment Strategies in Ovarian Cancer

September 1, 2020 - September 1, 2021

How have PARP inhibitors changed maintenance therapy for advanced ovarian cancer? Join Dr Michael Birrer and Dr Ursula Matulonis as they discuss recent clinical data related to the use of PARP inhibitors in maintenance therapy for advanced ovarian cancer, and highlight strategies to effectively prevent and manage treatment-related adverse effects. This activity is jointly provided by Postgraduate Institute for Medicine and Spire Learning. This activity is supported by an independent educational grant from Tesaro, a GSK company. Click on this link to access…

Find out more »
  • ONLINE ON-DEMAND

The Who, What, When & Why of Maintenance Therapy in Ovarian Cancer

September 1, 2020 - September 1, 2021

How have PARP inhibitors changed maintenance therapy for advanced ovarian cancer? Join Dr Michael Birrer and Dr Ursula Matulonis as they discuss recent clinical data related to the use of PARP inhibitors in maintenance therapy for advanced ovarian cancer, and highlight strategies to effectively prevent and manage treatment-related adverse effects. This activity is jointly provided by Postgraduate Institute for Medicine and Spire Learning. This activity is supported by an independent educational grant from Tesaro, a GSK company.   Click on this link to…

Find out more »

July 2020

  • ONLINE ON-DEMAND

A Novel Therapeutic Approach in Myeloid Malignancies: Targeting the Neddylation Pathway

July 28, 2020 - July 28, 2021

There is a lack of therapeutic options for the management of myeloid malignancies. So what are some emerging therapies that are available to patients? Join Mikkael A. Sekeres, MD, MS, and Sara M. Tinsley, PhD, ARNP, AOCNP during this podcast discussion and find out what novel therapeutic approaches are being evaluated for myeloid malignancies. This activity is jointly provided by Albert Einstein, Montefiore, and Spire Learning. This activity is supported by an independent educational grant from Takeda Oncology. Click on…

Find out more »

June 2020

  • ONLINE ON-DEMAND

Collaborating to Overcome Lifelong Challenges in Hemophilia A: Prophylaxis, Inhibitors, and Treatment Burden – A Gather-ed Activity

June 5, 2020 - June 4, 2021

This online CME program was developed to help clinicians create personalized treatment plans, utilize strategies to improve adherence, and implement plans for management of inhibitors in patients with hemophilia A. This Gather-ed is supported with self-study modules, live web discussions, and collaborative group tasks. The intent is to provide participants with an opportunity to improve their understanding of clinical information and to share experiences with peers. Online Gather-ed Peer-to-Peer Learning and Mentoring Initiative. Here is the link to sign up…

Find out more »
  • ONLINE ON-DEMAND

Joint Decision-Making in the Treatment of Tenosynovial Giant Cell Tumors: Balancing Benefits and Risks

June 3, 2020 - June 3, 2021

Tenosynovial giant cell tumor (TGCT) is a rare, nonmalignant tumor affecting the synovial lining of joints, bursae, and tendon sheaths. It is a potentially locally aggressive disease with high recurrence rates. In addition to agents used off-label for TGCT, the FDA recently approved the first medication specifically indicated for adult patients with symptomatic TGCT associated with severe morbidity or functional limitations and not amenable to improvement with surgery. This educational activity will ensure clinicians are better informed of the benefits…

Find out more »
+ Export Events